Inactive Instrument

Highlights Anthera Pharmaceuticals Inc Nasdaq

Equities

US03674U3005

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	18-03-12	CI
Anthera Mulls Acquisitions	18-03-06	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-05	CI
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	18-02-05	CI
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	17-12-11	CI
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	17-11-09	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-06	CI
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod	17-08-28	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-09	CI
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura	17-07-06	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-10	CI
Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy	17-04-10	CI
Anthera Pharmaceuticals, Inc. Announces Positive Results from the Extension Period of the Solution Study of Sollpura	17-03-29	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-02-27	CI
Anthera Pharmaceuticals Announces Phase 3 Solution Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results	16-12-27	CI
Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of Sollpura™ Following Positive DMC Review	16-12-13	CI
Anthera Pharmaceuticals, Inc. Updates on CHABLIS-SC1 Clinical Trial with Blisibimod	16-11-10	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-04	CI
Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™	16-08-16	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-08-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anthera Pharmaceuticals Inc Nasdaq

Equities

US03674U3005

Highlights

Filters